Mr. Elad Mark has served as Scinai’s COO since 2018. He is an executive leader and principal process engineer with over 15 consecutive years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification, and process validation.

Mr. Mark brings broad cGMP operational experience in biological process development and production. Prior to joining Scinai (then BiondVax), Mr. Mark led Novartis’s $800 million investment in a biologics facility in Singapore focused on drug substance manufacturing based on cell culture technology, designed to support both clinical and commercial production of potential new products that include monoclonal antibodies for use in helping patients with autoimmune, respiratory and oncology disorders. With Biopharmax and Antero, both global pharmaceutical engineering companies, Mr. Mark successfully led multiple projects in Israel, China, and Singapore.

Mr. Mark holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.